



PAVIA, ITALY

25 > 27 OCTOBER
2018

XI FORESIGHT TRAINING COURSE

CHANGES IN REGULATORY SCIENCES IN THE EU

how to move from a reactive
to a multi-stakeholder proactive attitude

ISTITUTI CLINICI SCIENTIFICI MAUGERI

Via Salvatore Maugeri, 6



XI FORESIGHT TRAINING COURSE

CHANGES IN REGULATORY SCIENCES IN THE EU

how to move from a reactive to a multi-stakeholder proactive attitude

PAVIA, ITALY

25 > 27 October, 2018

Change in Regulatory Sciences is a continuous challenging process! The challenge is to align scientific and patients' objectives with regulatory requirements along the whole development process of health products.

Moreover, all the stakeholders should be aware of the criteria by which the authorisation and access to products will be measured and decided to cover patients' specific needs. To ensure such an alignment, it is time to moving from a reactive regulation to a proactive involvement of all the involved parties, including users as well as producers.

This course is aimed at involving and networking people to properly understand the many novelties of the EU system and contributing to their implementation to anticipate good medicines and other products for human health and wellbeing on the market. The present Course will discuss the EU Pharmaceutical System novelties, with special focuses on three main topics. In addition, an initiative to set up a Regulatory Network will be presented.

MAIN TOPICS

Health data and health science

Health data represent a very crucial topic due to the increasing adoption of electronic technologies allowing FAIR data collection, interpretation, sharing and reuse in the developmental process of innovative health products ("health data science").

This large use of health data takes extraordinary advantage by the progress of the informatic technology as applied to health. In addition, 'health data science' should demonstrate high capacity to deal with the implementation of a new legal and regulatory approach to patients data protection and confidentiality following the General Data Protection Regulation (GDPR). A strong impact is expected from GDPR on data quality and reliability, consent and assent issues in all research activities sharing information, including clinical trials and studies.



XI FORESIGHT TRAINING COURSE

CHANGES IN REGULATORY SCIENCES IN THE EU

how to move from a reactive to a multi-stakeholder proactive attitude

PAVIA, ITALY

25 > 27 October, 2018

MAIN TOPICS

Medical devices

In April 2017, two new Regulations were adopted, (namely Regulation (EU) 2017/745 on medical devices, and Regulation (EU) 2017/746 on in vitro diagnostic medical devices) and entered into force on 25 May 2017. These replace the existing Directives and establish a modernised and more robust EU legislative framework to ensure better protection of public health and patient safety. The legislation now being in the form of a Regulation, rather than a Directive, means that the EU law is directly applicable at national level without requiring transposition through a specific national legislation. This should allow for greater legal certainty and prevent variation applied across EU Member States.

Rare diseases and Orphan Medicinal Product Regulation time for revision?

The Orphan Medicinal Products Regulation has obtained great results in the last 18 years. However, many rare diseases are still without any treatment and the harmonisation of the real availability of therapies for patients has not been yet achieved. For these two reasons, a revision of Regulation (EC) 141/2000 is expected soon. It will be mainly aimed to foster preclinical and clinical research of new treatments for rare diseases and to harmonise best practices and procedures for orphan medicines evaluation. What is expected is to overlap the current barriers and difficulties encountered in the new products developmental process and to reduce the inequalities derived by the geographical dispersion of patients and specialised centres. Special ethical and methodological issues will be explored.



XI FORESIGHT TRAINING COURSE

CHANGES IN REGULATORY SCIENCES IN THE EU

how to move from a reactive to a multi-stakeholder proactive attitude

PAVIA, ITALY

25 > 27 October, 2018

THURSDAY 25TH OCTOBER 2018

02,00 pm

Welcome address

Adriana Ceci, Maurizia Dossena

Enrico Bosone, *SIAR representative*

Stefano Govoni, *SIF representative*

Mario Melazzini, *ICSM representative*

Francesco Svelto, *UNIPV representative*

Guido Rasi, *EMA representative*

03,00 pm

Opening Session

**The role of the patients and healthcare professionals
in the regulatory framework**

Chairs: Adriana Ceci, Alan G Fraser

03,00 pm

EMA experience in supporting participation of patients and healthcare professionals in EU medicines regulation

Ivana Silva

EMA

03,30 pm

How has the role of patients got stronger and what they have learnt so far

François Houjéz

EURORDIS

04,00 pm

The evolving role of healthcare professionals in the regulatory field

Giovanni Migliaccio

Consorzio per Valutazioni Biologiche e Farmacologiche

04,30 pm

The COST programme to create networks in the scientific setting

Valentina Cardinale

Giulia Rotundo

Ministero dell'Istruzione, dell'Università e della Ricerca

05,00 pm

Presentation of COST proposal

Viviana Giannuzzi

Fondazione per la Ricerca Farmacologica Gianni Benzi Onlus; EMA-PDCO

05,30 pm

Discussion



XI FORESIGHT TRAINING COURSE

CHANGES IN REGULATORY SCIENCES IN THE EU

how to move from a reactive to a multi-stakeholder proactive attitude

PAVIA, ITALY

25 > 27 October, 2018

FRIDAY, 26TH OCTOBER 2018

09,00 am

First Session

Medical Devices: the new era in Europe

Chairs: Carla Caramella, Maurizia Dossena

09,00 am

Novelties and implementation of the Regulation 745-2017

Alan G Fraser

*European Society of Cardiology;
Cardiff University*

09,30 am

The new Regulations on medical devices and on in vitro diagnostics: a real revolution?

Franco Gattafoni

ACCREDIA

10,00 am

The challenges of the new Regulation from the Notified Bodies point of view

Luciana Gramiccioni

EUROFINS

Coffee break

11,00 am

The new provisions introduced by rule 21

Antonella Mamoli

IBSA Farmaceutici Italia

11,30 am

The manufacturing and control of medical devices in the perspective of the new regulation

Fabio Geremia

CTP System, Akka Life Sciences

12,00 am

The new regulation and the management of software and applications

Cettina Garufi

ACCREDIA

12,30 am

Conclusive remarks:

Carla Caramella, Maurizia Dossena

01,00 pm

Light lunch



XI FORESIGHT TRAINING COURSE

CHANGES IN REGULATORY SCIENCES IN THE EU

how to move from a reactive to a multi-stakeholder proactive attitude

PAVIA, ITALY

25 > 27 October, 2018

FRIDAY, 26TH OCTOBER 2018

02,00 pm

Second Session

Data Science supporting medicines and healthcare development

Chairs: Fedele Bonifazi, Victoria Hedley

02,00 pm

Big data & life sciences

Graziano Pesole

*Consiglio Nazionale delle Ricerche,
University of Bari,
ELIXIR*

02,30 pm

Data integration systems to support scientific research and patient enrolment in clinical studies

Riccardo Bellazzi

*Istituti Clinici Scientifici Maugeri,
University of Pavia*

03,00 pm

When rare becomes FAIR: a discussion on how to manage sensitive, rare disease data to enable large scale analysis

Marco Roos

Leiden University Medical Centre

03,30 pm

How to protect patients data in the light of the new Regulation?

Deborah Mascalzoni

CRB Uppsala University

04,00 pm

Industry perspective and Novartis experience

Roberto Orsenigo

Novartis Farma S.p.A.

04,30 pm

Conclusive remarks:

Claudio Carta, Paola Baiardi



XI FORESIGHT TRAINING COURSE

CHANGES IN REGULATORY SCIENCES IN THE EU

how to move from a reactive to a multi-stakeholder proactive attitude

PAVIA, ITALY

25 > 27 October, 2018

SATURDAY, 27TH OCTOBER 2018

09,00 am

Third Session

Orphan products and perspectives on the horizon

Chairs: François Houÿez, Donato Bonifazi

09,00 am

What member states have done so far at EU and national level

Agenzia Italiana del Farmaco
representative - TBC

09,30 am

Health outcomes of orphan medicines

Joseph Torrent-Farnell
Catalan Health Service

10,00 am

The demonstration of significant benefit in the EU framework

Laura Fregonese
EMA

10,30 am

Developing Advanced therapies for rare diseases in EU: opportunities and challenges in the experience of a Charity

Michela Gabaldo
Fondazione Telethon

11,00 am

The complexity of developing innovative medicines for rare diseases

Diego Ardigò
Chiesi Farmaceutici

11,30 am

Are patients satisfied from the implementation of EU policies on orphan medicines development and availability so far?

Dimitrios Athanasiou
World Duchenne Organization;
EMA-PDCO

12,00 am

Researchers, networks, new funds for rare diseases

Daria Julkowska
E-Rare

12,30 am

Conclusive remarks: expectations from the Orphan Medicines Regulation revision

Viviana Giannuzzi, Enrico Bosone



XI FORESIGHT TRAINING COURSE

CHANGES IN REGULATORY SCIENCES IN THE EU

how to move from a reactive to a multi-stakeholder proactive attitude

PAVIA, ITALY

25 > 27 October, 2018

SPEAKERS LIST

Ardigò	Diego	Chiesi Farmaceutici, R&D Rare Diseases Unit Head
Athanasiou	Dimitrios	World Duchenne Organization, Board Member; MDA Hellas, Member; European Medicines Agency, PDCO Member
Baiardi	Paola	Istituti Clinici Scientifici Maugeri, Scientific Coordinator; European Medicines Agency, PDCO Member
Bellazzi	Riccardo	Istituti Clinici Scientifici Maugeri, LIRSC Lab Director; Università degli Studi di Pavia, Department of Electrical, Computer and Biomedical Engineering Professor
Bonifazi	Donato	Consorzio per Valutazioni Biologiche e Farmacologiche, CEO; AICRO, President
Bonifazi	Fedele	Fondazione per la Ricerca Farmacologia Gianni Benzi Onlus, Vice-President and Secretary
Bosone	Enrico	Società Italiana Attività Regolatorie, President
Caramella	Carla	Università degli Studi di Pavia, Professor
Cardinale	Valentina	Ministero dell'Istruzione, dell'Università e della Ricerca, COST National Coordinator
Carta	Claudio	Istituto Superiore di Sanità, Researcher
Ceci	Adriana	Fondazione per la Ricerca Farmacologia Gianni Benzi Onlus, President
Dossena	Maurizia	Università degli Studi di Pavia, Professor
Fraser	Goldon Alan	European Society of Cardiology, Regulatory Affairs Committee Chairman; Cardiff University, Professor
Fregonese	Laura	European Medicines Agency, Scientific Officer
Gabaldo	Michela	Fondazione Telethon, Alliance Management & Regulatory Affairs Head
Garufi	Cettina	ACCREDIA, Medical Devices expert, Lead Auditor ISO 9001, ISO 13485, ISO 22716
Gattafoni	Franco	ACCREDIA, Medical Devices and In Vitro Diagnostic Expert, Lead Assessor ISO 17020, ISO 17021, ISO 17025, ISO 17065, ISO 15189
Geremia	Fabio	CTP System, Akka Life Sciences, Qualified Person Auditor and Senior Consultant, P&Q Northern Italy Responsible



XI FORESIGHT TRAINING COURSE

CHANGES IN REGULATORY SCIENCES IN THE EU

how to move from a reactive to a multi-stakeholder proactive attitude

PAVIA, ITALY

25 > 27 October, 2018

SPEAKERS LIST

Giannuzzi	Viviana	Fondazione per la Ricerca Farmacologica Gianni Benzi Onlus, Research Department Head; European Medicines Agency, PDCO Member
Govoni	Stefano	Società Italiana di Farmacologia, Scientific Committee Member
Gramiccioni	Luciana	Organismo notificato EUROFINS, Scientific Director
Hedley	Victoria	Newcastle University John Walton Muscular Dystrophy Research Centre - MRC Centre for Neuromuscular Diseases, Rare Disease Policy Manager
Houyez	Francois	EURORDIS, Treatment Information and Access Director, Health Policy Advisor
Julkowska	Daria	E-Rare, Scientific Coordinator
Mamoli	Antonella	IBSA Farmaceutici Italia, Regulatory Affairs Manager
Mascalzoni	Deborah	Public Health and Caring Sciences department, Centre for Research Ethics & Bioethics (CRB) Uppsala University, Senior Researcher
Melazzini	Mario	Istituti Clinici Scientifici Maugeri, Scientific Director
Migliaccio	Giovanni	Consorzio per Valutazioni Biologiche e Farmacologiche, Scientific Director
Orsenigo	Roberto	Novartis Farma S.p.A., Medical Franchise Leader Immunology, Hepatology and Dermatology
Pesole	Graziano	Consiglio Nazionale delle Ricerche, Director of the Institute of Biomembranes and Bioenergetics; University of Bari, professor; ELIXIR, Head of Italian Node
Rasi	Guido	European Medicines Agency, Executive Director
Roos	Marco	Leiden University Medical Centre, Assistant Professor
Rotundo	Giulia	Ministero dell'Istruzione, dell'Università e della Ricerca, Committee of Senior Officials of COST Association Member
Silva	Ivana	European Medicines Agency, Public Engagement Department, Stakeholders and Communication Division
Svelto	Francesco	Università degli Studi di Pavia, Vice-Rector
Torrent-Farnell	Joseph	Catalan Health Service, Medicine Division Head



XI FORESIGHT TRAINING COURSE

CHANGES IN REGULATORY SCIENCES IN THE EU

how to move from a reactive to a multi-stakeholder proactive attitude

PAVIA, ITALY

25 > 27 October, 2018

The **Gianni Benzi Pharmacological Research Foundation** is a non-profit scientific research organization founded in 2007 to uphold the ideas and continue the work of Professor Gianmartino Benzi.

Professor Benzi's forward-thinking idea was that the European pharmaceutical system can act as a key to both scientific development and economic growth, and that academia should be fully involved in it. As a result, he worked tirelessly on behalf of EMEA from 1989 to 2006.

He founded in Pavia the first Interdisciplinary and International Regulatory Science School in Europe.

Today, the Gianni Benzi Foundation is embracing his heritage by providing high-level training for Regulatory Sciences at a Europe-wide level, including the annual Foresight Training Courses, short-term international courses for highly-specialized professionals in the various fields of Regulatory Sciences. Each course is focused on the most recent innovation and advancement in the field and aims to put together different stakeholders and experts in the sector willing to share their experiences and knowledge.

COURSE SCIENTIFIC COMMITTEE

Paola Baiardi | *Istituti Clinici Scientifici Maugeri*

Enrico Bosone | *Società Italiana Attività Regolatorie*

Maurizia Dossena | *Università di Pavia*

Viviana Giannuzzi | *Fondazione per la Ricerca Farmacologica Gianni Benzi Onlus*

PAVIA, ITALY
25 > 27 OCTOBER
2018

XI FORESIGHT TRAINING COURSE

CHANGES IN REGULATORY SCIENCES IN THE EU

how to move from a reactive
to a multi-stakeholder proactive attitude

ORGANISED BY

Fondazione per la Ricerca Farmacologica
Gianni Benzi Onlus

Master in Discipline Regolatorie
'Gianni Benzi' - Università di Pavia



Master Biennale di II livello in
Discipline Regolatorie "G. Benzi"

IN COLLABORATION WITH

Istituti Clinici Scientifici Maugeri

Società Italiana Attività Regolatorie



SUPPORTED BY

Farmindustria
Associazione delle imprese del farmaco

Società Italiana
di Farmacologia



Agenzia Italiana del Farmaco

Università di Pavia



Istituto Superiore di Sanità

Associazione Italiana Contract
Research Organization



Rete Italiana Comitati Etici
Ricercatori e Cittadini

Regione Lombardia

